US5041578A - Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents - Google Patents

Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents Download PDF

Info

Publication number
US5041578A
US5041578A US07/274,824 US27482488A US5041578A US 5041578 A US5041578 A US 5041578A US 27482488 A US27482488 A US 27482488A US 5041578 A US5041578 A US 5041578A
Authority
US
United States
Prior art keywords
trans
platinum
diaminocyclohexane
dichloro
cyclobutanedicarboxylato
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/274,824
Inventor
Abdul R. Khokhar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Assigned to BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM reassignment BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: KHOKHAR, ABDUL R., NEWMAN, ROBERT A., SIDDIK, ZAHID H.
Priority to US07/274,824 priority Critical patent/US5041578A/en
Priority to PCT/US1989/004644 priority patent/WO1990005734A1/en
Priority to AU44849/89A priority patent/AU4484989A/en
Publication of US5041578A publication Critical patent/US5041578A/en
Application granted granted Critical
Priority to US07/927,201 priority patent/US5318962A/en
Priority to US07978788 priority patent/US5288887B1/en
Priority to US08/200,395 priority patent/US5393909A/en
Priority to US08/316,139 priority patent/US5434256A/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage

Definitions

  • the present invention relates to platinum based drugs and methods of using such drugs and formulations thereof in antitumor therapy.
  • platinum based drugs are known to have useful antitumor activity. However, such drugs are also known to have various drawbacks. For example, cisplatin is one such drug with a significant level of activity, but which also exhibits significant nephrotoxicity. Other platinum drugs have been synthesized which have less potential to cause renal injury, but many of these drugs are much less soluble in water than is desirable.
  • the present invention includes complexes having the formula ##STR2## and stereoisomers thereof, where Z 1 and Z 2 are halogens and X is selected from the group consisting of sulfate, phosphate, nitrate, monocarboxylate, and dicarboxylate.
  • X is selected from the group consisting of malonate, cycloalkanemonocarboxylate, cycloalkenemonocarboxylate, cycloalkanedicarboxylate, and cycloalkenedicarboxylate.
  • Another embodiment of the present invention concerns complexes having the formula ##STR3## and stereoisomers thereof, where X is selected from the group consisting of 1,1-cyclobutanedicarboxylate, cyclobutanemonocarboxylate, and malonate.
  • the present invention relates to trans-dichloro (1,2-diaminocyclohexane) platinum (IV) complexes, where the complex additionally includes a ligand selected from the above-mentioned group.
  • the present invention also concerns antitumor compositions which include an effective amount of one or more above-described compounds, and a pharmaceutically acceptable carrier. Additionally, the present invention concerns methods of inhibiting neoplastic cell growth, which include the step of administering to a mammal an effective amount of one or more of the above-described complexes.
  • the complexes, compositions, and methods of the present invention possess significant advantages over the prior art.
  • Platinum (IV) complexes in accordance with the present invention possess high aqueous solubility, high antitumor activity, a broad spectrum of activity, and a lack of cross resistance to other antitumor drugs such as cisplatin. Therefore, the complexes, compositions, and methods of the present invention are believed to have significant therapeutic advantages in the treatment of neoplastic disease states.
  • complexes in accordance with the present invention include the following:
  • the reaction was initiated by the addition of a solution of potassium iodide (28 g, 168 mmol in 50 ml of water) to a filtered aqueous solution of K 2 PtCl 4 (12 g, 28.9 mmol) in 200 ml of water.
  • DACH Trans-R,R-1,2-diaminocyclohexane
  • II The brown solid, cis-diiodo-DACH-platinum (II) was removed by filtration and washed successively with H 2 O, methanol, and ether. After the final product was dried under vacuum, the final yield was 86%.
  • DACH-Pt-1,1-cyclobutanedicarboxylate was synthesized by dissolving sulfato-DACH-platinum (0.5447 g) in 20 ml of water and adding to it sodium 1,1-cyclobutanedicarboxylate prepared in situ by the addition of 0.5 ml of 5N NaOH and 0.187 g of 1,1-cyclobutanedicarboxylic acid in 10 ml of water. The reaction mixture was stirred at room temperature for 20 hours, and the white precipitate was separated by filtration and washed with cold water, ethanol, and ether. The final product was recrystallized from water.
  • Trans-dichloro(DACH)Pt(IV)-1,1-cyclobutanedicarboxylate was synthesized by adding 125 ml of 0.02N HCl (0.723 mg/ml) to a suspension of DACH-Pt(IV) (OH) 2 1,1-cyclobutanedicarboxylate (0.606 g in 10 ml of water), and leaving the suspension stirring for 30 minutes at room temperature.
  • the light yellow solution was filtered, and the volume of the filtrate was reduced under vacuum to 2 ml.
  • the light yellow product was separated by filtration, washed with 2 ⁇ 2 ml of cold water, and dried under vacuum to give 78% of the final product.
  • the antitumor activity of complexes in accordance with the present invention was tested by injecting L1210 murine leukemia cells (100,000) intraperitoneally into BDF1 mice on day 0.
  • the six above-listed compounds, as well as cisplatin, were injected intraperitoneally on days 1, 5, and 9 at dose levels ranging from 1.56 mg/kg to 200 mg/kg.
  • Table 3 below gives for each complex the optimal dose that appeared from this test, as well as the percent T/C (median survival time of treated mice/median survival time of control mice ⁇ 100)
  • compositions in accordance with the present invention can suitably include a pharmaceutically effective amount of one or more platinum complexes in accordance with the present invention, and a pharmaceutically acceptable carrier, such as, for example, water, saline, or dextrose solution.
  • a pharmaceutically acceptable carrier such as, for example, water, saline, or dextrose solution.
  • Compositions in accordance with the present invention will contain between about 0.001% and about 99% by weight active complexes, preferably between about 0.001% and about 10%.
  • Methods in accordance with the present invention comprise administering to a mammal an effective amount of the compounds or compositions described above.
  • the administering step can suitably be parenteral and by intravenous, intraarterial, intramuscular, intralymphatic, intraperitoneal, subcutaneous, intrapleural, or intrathecal injection, or by topical application or oral dosage.
  • Such administration is preferably repeated on a timed schedule until tumor regression or disappearance has been achieved, and may be used in conjunction with other forms of tumor therapy such as surgery or chemotherapy with different agents.

Abstract

Water-soluble complexes having the formula: ##STR1## and stereoisomers thereof, where Z1 and Z2 are halogens and X is selected from the group consisting of sulfate, phosphate, nitrate, monocarboxylate, and dicarboxylate, have been found to have desirable antitumor activity, as well as relatively low levels of toxicity.

Description

The U.S. government may own certain rights in this invention pursuant to National Cancer Institute grant No. RO1-CA-41581.
FIELD OF THE INVENTION
The present invention relates to platinum based drugs and methods of using such drugs and formulations thereof in antitumor therapy.
BACKGROUND OF THE INVENTION
Some platinum based drugs are known to have useful antitumor activity. However, such drugs are also known to have various drawbacks. For example, cisplatin is one such drug with a significant level of activity, but which also exhibits significant nephrotoxicity. Other platinum drugs have been synthesized which have less potential to cause renal injury, but many of these drugs are much less soluble in water than is desirable.
A long standing need exists for platinum drugs which will have improved aqueous solubility and antitumor activity, a broader spectrum of activity against various neoplastic disease states, and also a lack of cross resistance to other antitumor drugs such as cisplatin.
SUMMARY OF THE INVENTION
The present invention includes complexes having the formula ##STR2## and stereoisomers thereof, where Z1 and Z2 are halogens and X is selected from the group consisting of sulfate, phosphate, nitrate, monocarboxylate, and dicarboxylate. In a preferred embodiment, X is selected from the group consisting of malonate, cycloalkanemonocarboxylate, cycloalkenemonocarboxylate, cycloalkanedicarboxylate, and cycloalkenedicarboxylate.
Another embodiment of the present invention concerns complexes having the formula ##STR3## and stereoisomers thereof, where X is selected from the group consisting of 1,1-cyclobutanedicarboxylate, cyclobutanemonocarboxylate, and malonate. In yet another aspect, the present invention relates to trans-dichloro (1,2-diaminocyclohexane) platinum (IV) complexes, where the complex additionally includes a ligand selected from the above-mentioned group.
The present invention also concerns antitumor compositions which include an effective amount of one or more above-described compounds, and a pharmaceutically acceptable carrier. Additionally, the present invention concerns methods of inhibiting neoplastic cell growth, which include the step of administering to a mammal an effective amount of one or more of the above-described complexes.
The complexes, compositions, and methods of the present invention possess significant advantages over the prior art. Platinum (IV) complexes in accordance with the present invention possess high aqueous solubility, high antitumor activity, a broad spectrum of activity, and a lack of cross resistance to other antitumor drugs such as cisplatin. Therefore, the complexes, compositions, and methods of the present invention are believed to have significant therapeutic advantages in the treatment of neoplastic disease states.
DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENTS
Specific examples of complexes in accordance with the present invention include the following:
______________________________________                                    
Complex Complex                                                           
No.     Name                                                              
______________________________________                                    
1.      Trans-dichloro(1,1-cyclobutanedicarboxylato)                      
        (trans-1,2-diaminocyclohexane) platinum (IV)                      
2.      Trans-dichloro(1,1-cyclobutanedicarboxylato)                      
        (trans- .sub.-- R, .sub.-- R-1,2-diaminocyclohexane) platinum     
        (IV)                                                              
3.      Trans-dichloro(1,1-cyclobutanedicarboxylato)                      
        (trans- .sub.-- S, .sub.-- S-1,2-diaminocyclohexane) platinum     
        (IV)                                                              
4.      Trans-dichloro(1,1-cyclobutanedicarboxylato)                      
        (cis-1,2-diaminocyclohexane) platinum (IV)                        
5.      Trans-dichloro(cyclobutanecarboxylato) (OH)                       
        (trans-1,2-diaminocyclohexane) platinum (IV)                      
6.      Trans-dichloro(malonato) (cis, trans-1,2-                         
        diaminocyclohexane) platinum (IV)                                 
______________________________________
An example of the synthesis of a complex in accordance with the present invention is as follows.
The reaction was initiated by the addition of a solution of potassium iodide (28 g, 168 mmol in 50 ml of water) to a filtered aqueous solution of K2 PtCl4 (12 g, 28.9 mmol) in 200 ml of water. Trans-R,R-1,2-diaminocyclohexane (DACH) (3.5 g, 30.7 mmol) in 10 ml of water was added dropwise to the solution of K2 PtI4 and stirring was continued for one hour at room temperature. The brown solid, cis-diiodo-DACH-platinum (II), was removed by filtration and washed successively with H2 O, methanol, and ether. After the final product was dried under vacuum, the final yield was 86%.
To prepare the water-soluble sulfato-DACH-platinum, cis-diiodo-DACH-platinum (II) (16.88 g, 0.03 mol) was added to a solution of Ag2 SO4 (8.88 g, 0.0285 mol) in 1800 ml of water. The reaction mixture was stirred overnight at room temperature (protected from light) and the precipitated AgI was removed by filtration. The yellow solution was evaporated to dryness at 45° C. under reduced pressure. A yellow product was obtained which was further purified from water. The yield of sulfato-DACH-platinum was 95%.
DACH-Pt-1,1-cyclobutanedicarboxylate was synthesized by dissolving sulfato-DACH-platinum (0.5447 g) in 20 ml of water and adding to it sodium 1,1-cyclobutanedicarboxylate prepared in situ by the addition of 0.5 ml of 5N NaOH and 0.187 g of 1,1-cyclobutanedicarboxylic acid in 10 ml of water. The reaction mixture was stirred at room temperature for 20 hours, and the white precipitate was separated by filtration and washed with cold water, ethanol, and ether. The final product was recrystallized from water. Hydrogen peroxide (4 ml, 30%) was added to a suspension of DACH-Pt-1,1-cyclobutanedicarboxylate (0.64 g in 100 ml of water). The reaction mixture was left stirring for one hour at 45° C. The clear solution was filtered and the volume of the filtrate was reduced to about 3 ml, and white precipitate was separated by filtration, washed with 3×2 ml of cold water, acetone, ether, and dried under vacuum to give a yield of 91%.
Trans-dichloro(DACH)Pt(IV)-1,1-cyclobutanedicarboxylate was synthesized by adding 125 ml of 0.02N HCl (0.723 mg/ml) to a suspension of DACH-Pt(IV) (OH)2 1,1-cyclobutanedicarboxylate (0.606 g in 10 ml of water), and leaving the suspension stirring for 30 minutes at room temperature. The light yellow solution was filtered, and the volume of the filtrate was reduced under vacuum to 2 ml. The light yellow product was separated by filtration, washed with 2×2 ml of cold water, and dried under vacuum to give 78% of the final product.
The above mentioned procedure can be used to synthesize compounds in accordance with the present invention. Cyclobutanemonocarboxylic acid or malonic acid can be substituted for 1,1-cyclobutanedicarboxylic acid in this procedure.
Analytical and spectroscopic data for the six complexes listed above are given in Tables 1 and 2, respectively.
              TABLE 1                                                     
______________________________________                                    
Complex Observed %     Calculated (%)                                     
No.     C      H        N    C       N    N                               
______________________________________                                    
1       27.87  4.1      5.09 26.67   4.07 5.18                            
2       25.83  4.42     4.72 25.80   4.30 5.01                            
3       26.11  4.66     4.69 25.80   4.30 5.01                            
4       24.83  4.29     4.69 25.80   4.30 5.01                            
5       26.61  4.43     5.64 26.90   4.70 5.01                            
6       22.08  3.51     5.76 22.00   3.46 5.70                            
______________________________________                                    

              TABLE 2                                                     
______________________________________                                    
Complex                                                                   
No.        ν C = O(cm.sup.-1)                                          
                        ν C = O(cm.sup.-1)                             
______________________________________                                    
1          1660, 1628   1345                                              
2          1660, 1628   1345                                              
3          1660, 1628   1344                                              
4          1660, 1628   1345                                              
5          1660         1363                                              
6          1655, 1639   1345                                              
______________________________________
The antitumor activity of complexes in accordance with the present invention was tested by injecting L1210 murine leukemia cells (100,000) intraperitoneally into BDF1 mice on day 0. The six above-listed compounds, as well as cisplatin, were injected intraperitoneally on days 1, 5, and 9 at dose levels ranging from 1.56 mg/kg to 200 mg/kg. Table 3 below gives for each complex the optimal dose that appeared from this test, as well as the percent T/C (median survival time of treated mice/median survival time of control mice×100)
              TABLE 3                                                     
______________________________________                                    
          Optimal Dose                                                    
Complex   (mg/kg)           % T/C                                         
______________________________________                                    
1         50                253                                           
2         50                471 (2/5)*                                    
3         100               329 (1/5)                                     
4         100               388 (1/5)                                     
5         12.5              388 (2/5)                                     
6         50                167                                           
Cisplatin 3                 218                                           
______________________________________                                    
 *Numbers in parentheses indicates number of animals cured/number of      
 animals treated.
The spectrum of antitumor activity of platinum complex number 1 was tested by injecting four different types of murine tumor cells intraperitoneally into BDF1 mice on day 0. One hundred thousand cells were injected for L1210 and L1210/cisplatin, while 1,000,000 Cells were injected for M5076, and 0.5 ml of a 10% brei for B-16. Complex 1 (25 mg/kg) or cisplatin (3 mg/kg) were injected on days 1, 5, and 9 in the case of L1210, 1210/cisplatin, and B-16, and on days 1, 5, 9, and 13 for M5076. The results of this test are shown in Table 4.
              TABLE 4                                                     
______________________________________                                    
Murine Tumor    % T/C                                                     
Model           Complex 1 Cisplatin                                       
______________________________________                                    
L1210           171       218                                             
L1210/cisplatin 167        94                                             
B-16            232       139                                             
M5076           197 (1/5)*                                                
                          265                                             
______________________________________                                    
 *Numbers in parentheses indicates number of animals cured/number of      
 animals treated.
Compositions in accordance with the present invention can suitably include a pharmaceutically effective amount of one or more platinum complexes in accordance with the present invention, and a pharmaceutically acceptable carrier, such as, for example, water, saline, or dextrose solution. Compositions in accordance with the present invention will contain between about 0.001% and about 99% by weight active complexes, preferably between about 0.001% and about 10%.
Methods in accordance with the present invention comprise administering to a mammal an effective amount of the compounds or compositions described above. The administering step can suitably be parenteral and by intravenous, intraarterial, intramuscular, intralymphatic, intraperitoneal, subcutaneous, intrapleural, or intrathecal injection, or by topical application or oral dosage. Such administration is preferably repeated on a timed schedule until tumor regression or disappearance has been achieved, and may be used in conjunction with other forms of tumor therapy such as surgery or chemotherapy with different agents.
The description and examples given in this patent are intended to illustrate the present invention. They are not intended to be an exhaustive list of all possible specific embodiments of the present invention. Those skilled in the art will recognize that modifications could be made to the specific embodiments listed here which would still be within the scope of the present invention.

Claims (10)

We claim:
1. A platinum complex selected from the group consisting of trans-dichloro(1,1-cyclobutanedicarboxylato) (trans-1,2-diaminocyclohexane) platinum (IV), trans-dichloro(1,1-cyclobutanedicarboxylato) trans-R,R-1,2-diaminocyclohexane) platinum (IV), trans-dichloro(1,1-cyclobutanedicarboxylato) (trans-S,S 1,2-diaminocyclohexane) platinum (IV), trans-dichloro(1,1-cyclobutanedicarboxylato) (cis 1,2-diaminocyclohexane) platinum (IV).
2. An anti-tumor composition which includes an effective amount of a platinum complex selected from the group consisting of trans-dichloro(1,1-cyclobutanedicarboxylato) (trans-1,2-diaminocyclohexane) platinum (IV), trans-dichloro(1,1-cyclobutanedicarboxylato) trans-R,R-1,2-diaminocyclohexane) platinum (IV), trans-dichloro(1,1-cyclobutanedicarboxylato) (trans-S,S-1,2-diaminocyclohexane) platinum (IV), transdichloro(1,1-cyclobutanedicarboxylato) (cis-1,2-diaminocyclohexane) platinum (IV); and a pharmaceutically acceptable carrier.
3. Trans-dichloro(1,1-cyclobutanedicarboxylato) (trans-1,2-diaminocyclohexane) platinum (IV).
4. Trans-dichloro(1,1-cyclobutanedicarboxylato) (trans-R,R-1,2-diaminocyclohexane) platinum (IV).
5. Trans dichloro(1,1-cyclobutanedicarboxylato) trans-S,S-1,2-diaminocyclohexane) platinum (IV).
6. Trans-dichloro(1,1-cyclobutanedicarboxylato) (cis-1,2-diaminocyclohexane) platinum (IV).
7. An antitumor composition which includes an effective amount of trans-dichloro(1,1-cyclobutanedicarboxylato) (trans-1,2-diaminocyclohexane)platinum (IV); and a pharmaceutically acceptable carrier.
8. An antitumor composition which includes an effective amount of trans-dichloro(1,1-cyclobutanedicarboxylato) (trans-R,R-1,2-diaminocyclohexane) platinum (IV); and a pharmaceutically acceptable carrier.
9. An antitumor composition which includes an effective amount of trans-dichloro(1,1-cyclobutanedicarboxylato) (trans-S,S-1,2-diaminocyclohexane) platinum (IV); and a pharmaceutically acceptable carrier.
10. An antitumor composition which includes an effective amount of trans-dichloro(1,1-cyclobutanedicarboxylato) (cis-1,2-diaminocyclohexane) platinum (IV); and a pharmaceutically acceptable carrier.
US07/274,824 1988-11-22 1988-11-22 Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents Expired - Lifetime US5041578A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US07/274,824 US5041578A (en) 1988-11-22 1988-11-22 Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
PCT/US1989/004644 WO1990005734A1 (en) 1988-11-22 1989-10-17 Water soluble 1,2-diaminocyclohexane platinum (iv) complexes as antitumor agents
AU44849/89A AU4484989A (en) 1988-11-22 1989-10-17 Water soluble 1,2-diaminocyclohexane platinum (iv) complexes as antitumor agents
US07/927,201 US5318962A (en) 1988-11-22 1992-08-07 Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
US07978788 US5288887B1 (en) 1988-11-22 1992-11-19 Diamine platinum(iv) complexes having mixed carboxylate ligands as antitumor agents
US08/200,395 US5393909A (en) 1988-11-22 1994-02-23 Diamine platinum complexes as antitumor agents
US08/316,139 US5434256A (en) 1988-11-22 1994-09-30 Diamine platinum complexes as antitumor agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/274,824 US5041578A (en) 1988-11-22 1988-11-22 Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US62479590A Division 1988-11-22 1990-12-07

Publications (1)

Publication Number Publication Date
US5041578A true US5041578A (en) 1991-08-20

Family

ID=23049753

Family Applications (3)

Application Number Title Priority Date Filing Date
US07/274,824 Expired - Lifetime US5041578A (en) 1988-11-22 1988-11-22 Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
US07/927,201 Expired - Lifetime US5318962A (en) 1988-11-22 1992-08-07 Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
US07978788 Expired - Fee Related US5288887B1 (en) 1988-11-22 1992-11-19 Diamine platinum(iv) complexes having mixed carboxylate ligands as antitumor agents

Family Applications After (2)

Application Number Title Priority Date Filing Date
US07/927,201 Expired - Lifetime US5318962A (en) 1988-11-22 1992-08-07 Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
US07978788 Expired - Fee Related US5288887B1 (en) 1988-11-22 1992-11-19 Diamine platinum(iv) complexes having mixed carboxylate ligands as antitumor agents

Country Status (3)

Country Link
US (3) US5041578A (en)
AU (1) AU4484989A (en)
WO (1) WO1990005734A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393909A (en) * 1988-11-22 1995-02-28 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5434256A (en) * 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5843475A (en) * 1996-12-06 1998-12-01 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
EP2266607A2 (en) 1999-10-01 2010-12-29 Immunogen, Inc. Immunoconjugates for treating cancer
CN107709286A (en) * 2015-06-24 2018-02-16 日本化药株式会社 New platinum (IV) complex compound
US10596191B2 (en) 2015-09-14 2020-03-24 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of hexa-coordinated platinum complex

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI905018A0 (en) * 1989-10-17 1990-10-12 Bristol Myers Squibb Co I VATTEN OCH LOESNINGSMEDEL LOESLIGA AXIALA HYDROXI-OCH MONO- OCH DIKARBOXYLSYRADERIVAT MED STOR TUMOERAKTIVITET.
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
EP0646589A3 (en) * 1993-10-04 1995-06-28 Tanaka Precious Metal Ind Anti-tumor platinum (IV) complex.
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
JPH10251285A (en) * 1997-03-14 1998-09-22 Ss Pharmaceut Co Ltd Platinum (iv) complex and medicine containing the same
KR100246722B1 (en) * 1997-12-30 2000-04-01 박호군 Oral platium(iv) antitumor agents and their preparation method
WO1999062551A1 (en) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
KR100317473B1 (en) * 1999-05-11 2001-12-22 이계호 Novel Pt(IV) complex and preparing method thereof
CN102603812B (en) * 2012-03-09 2015-11-18 江苏省原子医学研究所 A kind of Binuclear platinum (II) – Zoledronic acid title complex and Synthesis and applications thereof
CN102731580B (en) * 2012-07-12 2015-07-01 江苏省原子医学研究所 Binuclear platinum (II)-diphosphonic acid coordination compound, preparation method and application thereof
WO2015102922A1 (en) * 2013-12-31 2015-07-09 Blend Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
EP3157515B1 (en) 2014-06-23 2021-05-26 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904663A (en) * 1972-04-10 1975-09-09 Rustenburg Platinum Mines Ltd Compositions containing platinum
US4115418A (en) * 1976-09-02 1978-09-19 Government Of The United States Of America 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity
US4137248A (en) * 1977-08-29 1979-01-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Compound, 4-carboxyphthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof
US4140707A (en) * 1972-06-08 1979-02-20 Research Corporation Malonato platinum anti-tumor compounds
US4169846A (en) * 1976-09-06 1979-10-02 Kenji Inagaki Cis-platinum (ii) complex of trans-l-1,2-diaminocyclohexane
US4203912A (en) * 1977-10-19 1980-05-20 Johnson, Matthey & Co., Limited Compositions containing platinum
US4225529A (en) * 1977-10-19 1980-09-30 Johnson, Matthey & Co., Limited Compositions containing platinum
US4230631A (en) * 1977-10-19 1980-10-28 Johnson, Matthey & Co., Limited Platinum coordination compounds
US4256652A (en) * 1977-09-12 1981-03-17 Yoshinori Kidani Platinum complex
US4271085A (en) * 1979-06-20 1981-06-02 Engelhard Minerals & Chemicals Corporation Cis-platinum (II) amine lactate complexes
US4431666A (en) * 1980-01-03 1984-02-14 Nederlandse Centrale Organisatie Voor Toegepast Natuurwelenschappelyk Onderzoek Platinum(IV)-diamine complexes, a process for the preparation thereof, a process for the preparation of a medicine using such a platinum(IV)-diamine complex for the treatment of malignant tumors in mice
BE898614A (en) * 1984-01-05 1984-05-02 Abello Quimicos Farma Prod Sa Antitumour and antiparasitic platinum complexes - contg. 1,2-di:amino-cyclohexane ligand
EP0113508A1 (en) * 1982-11-04 1984-07-18 Inco Research & Development Center, Inc. Hydrophobic platinum compounds and their preparation
US4466924A (en) * 1981-03-03 1984-08-21 Nederlandse Centrale Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Platinum-diamine complexes, a process for the preparation thereof, a process for the preparation of a medicine using such a platinum-diamine complex for the treatment of malignant tumors in mice as well as a medicine thus formed
EP0130482A1 (en) * 1983-06-20 1985-01-09 Research Corporation Diaminocyclohexane platinum complexes, process for preparing same and pharmaceutical compositions containing same
EP0136012A1 (en) * 1983-08-05 1985-04-03 Yoshinori Kidani Cytostatic platinum complexes
EP0147926A2 (en) * 1983-10-21 1985-07-10 Johnson Matthey Public Limited Company Oral anti-cancer compositions
GB2160867A (en) * 1984-06-20 1986-01-02 Shionogi & Co Platinum (iv) complexes
EP0193936A1 (en) * 1985-03-06 1986-09-10 Sumitomo Pharmaceuticals Company, Limited Liposoluble platinum (II) complex and preparation thereof
US4657927A (en) * 1978-05-04 1987-04-14 Research Corporation Malonato platinum compounds
WO1987002364A1 (en) * 1985-10-18 1987-04-23 Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US4661516A (en) * 1983-06-20 1987-04-28 Research Corporation Diaminocyclohexane platinum complexes
US4680308A (en) * 1985-12-26 1987-07-14 Andrulis Research Corporation Stable soluble 1,2-diaminocyclohexane platinum complexes
EP0237450A2 (en) * 1986-03-07 1987-09-16 Yoshinori Kidani Platinum (IV) complexes
WO1988003925A1 (en) * 1986-11-17 1988-06-02 Board Of Regents, The University Of Texas System 1,2-diaminocyclohexane-platinum complexes with antitumor activity
US4760155A (en) * 1984-06-27 1988-07-26 Heffernan James G Platinum co-ordination compounds
US4760157A (en) * 1986-01-31 1988-07-26 American Cyanamid Company (2,2,-bis(aminomethyl)-1,3-propanediol-N,N')platinum complexes
US4760156A (en) * 1984-06-27 1988-07-26 Heffernan James G Platinum co-ordination compounds
US4861905A (en) * 1987-02-19 1989-08-29 Nippon Kayaku Kabushiki Kaisha Platinum complexes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67789A (en) * 1983-01-31 1986-09-30 Yissum Res Dev Co Amino-substituted malonato platinum(ii)complexes and method for their preparation
US4716157A (en) * 1986-03-20 1987-12-29 American Cyanamid Company Heterocyclic-1,2-diamine platinum complexes
US5206400A (en) * 1986-07-07 1993-04-27 Ohio State University Diastereomeric mono- and di-substituted diamino cyclohexane compounds and the method of preparation thereof

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904663A (en) * 1972-04-10 1975-09-09 Rustenburg Platinum Mines Ltd Compositions containing platinum
US4140707A (en) * 1972-06-08 1979-02-20 Research Corporation Malonato platinum anti-tumor compounds
US4140707B1 (en) * 1972-06-08 1989-12-19
US4115418A (en) * 1976-09-02 1978-09-19 Government Of The United States Of America 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity
US4169846A (en) * 1976-09-06 1979-10-02 Kenji Inagaki Cis-platinum (ii) complex of trans-l-1,2-diaminocyclohexane
US4137248A (en) * 1977-08-29 1979-01-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Compound, 4-carboxyphthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof
US4256652A (en) * 1977-09-12 1981-03-17 Yoshinori Kidani Platinum complex
US4225529A (en) * 1977-10-19 1980-09-30 Johnson, Matthey & Co., Limited Compositions containing platinum
US4230631A (en) * 1977-10-19 1980-10-28 Johnson, Matthey & Co., Limited Platinum coordination compounds
US4203912A (en) * 1977-10-19 1980-05-20 Johnson, Matthey & Co., Limited Compositions containing platinum
US4657927A (en) * 1978-05-04 1987-04-14 Research Corporation Malonato platinum compounds
US4271085A (en) * 1979-06-20 1981-06-02 Engelhard Minerals & Chemicals Corporation Cis-platinum (II) amine lactate complexes
US4431666A (en) * 1980-01-03 1984-02-14 Nederlandse Centrale Organisatie Voor Toegepast Natuurwelenschappelyk Onderzoek Platinum(IV)-diamine complexes, a process for the preparation thereof, a process for the preparation of a medicine using such a platinum(IV)-diamine complex for the treatment of malignant tumors in mice
US4466924A (en) * 1981-03-03 1984-08-21 Nederlandse Centrale Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Platinum-diamine complexes, a process for the preparation thereof, a process for the preparation of a medicine using such a platinum-diamine complex for the treatment of malignant tumors in mice as well as a medicine thus formed
EP0113508A1 (en) * 1982-11-04 1984-07-18 Inco Research & Development Center, Inc. Hydrophobic platinum compounds and their preparation
EP0130482A1 (en) * 1983-06-20 1985-01-09 Research Corporation Diaminocyclohexane platinum complexes, process for preparing same and pharmaceutical compositions containing same
US4661516A (en) * 1983-06-20 1987-04-28 Research Corporation Diaminocyclohexane platinum complexes
EP0136012A1 (en) * 1983-08-05 1985-04-03 Yoshinori Kidani Cytostatic platinum complexes
EP0147926A2 (en) * 1983-10-21 1985-07-10 Johnson Matthey Public Limited Company Oral anti-cancer compositions
BE898614A (en) * 1984-01-05 1984-05-02 Abello Quimicos Farma Prod Sa Antitumour and antiparasitic platinum complexes - contg. 1,2-di:amino-cyclohexane ligand
GB2160867A (en) * 1984-06-20 1986-01-02 Shionogi & Co Platinum (iv) complexes
US4760155A (en) * 1984-06-27 1988-07-26 Heffernan James G Platinum co-ordination compounds
US4760156A (en) * 1984-06-27 1988-07-26 Heffernan James G Platinum co-ordination compounds
EP0193936A1 (en) * 1985-03-06 1986-09-10 Sumitomo Pharmaceuticals Company, Limited Liposoluble platinum (II) complex and preparation thereof
WO1987002364A1 (en) * 1985-10-18 1987-04-23 Board Of Regents, The University Of Texas System Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US4680308A (en) * 1985-12-26 1987-07-14 Andrulis Research Corporation Stable soluble 1,2-diaminocyclohexane platinum complexes
US4760157A (en) * 1986-01-31 1988-07-26 American Cyanamid Company (2,2,-bis(aminomethyl)-1,3-propanediol-N,N')platinum complexes
EP0237450A2 (en) * 1986-03-07 1987-09-16 Yoshinori Kidani Platinum (IV) complexes
US4845124A (en) * 1986-03-07 1989-07-04 Yoshinori Kidani Platinum (IV) complexes
WO1988003925A1 (en) * 1986-11-17 1988-06-02 Board Of Regents, The University Of Texas System 1,2-diaminocyclohexane-platinum complexes with antitumor activity
US4861905A (en) * 1987-02-19 1989-08-29 Nippon Kayaku Kabushiki Kaisha Platinum complexes

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
Appleton, Chemical Abstracts 101:182656c (1984). *
Burchenal, Chemical Abstracts 93:1125661t (1980). *
Connors, Chem. Biol. Interactions, 5:415 424 (1972). *
Connors, Chem. Biol. Interactions, 5:415-424 (1972).
Craciunescu, Eur., J. Med. Chem. 353 357 (1984). *
Craciunescu, Eur., J. Med. Chem. 353-357 (1984).
Delicoonstantinos, Biochem. Soc. Trans. 5(5):1326 1329 (1977). *
Delicoonstantinos, Biochem. Soc. Trans. 5(5):1326-1329 (1977).
Freise, Archives Internationales de Pharmacodynamie et de Therapie No. 258 No. 2, Aug. 1982. *
Freise, Archives Internationales de Pharmacodynamie et de Therapie No. 258-No. 2, Aug. 1982.
Kaledin, Jncl. vol. 66, No. 5, May 1981. *
Khokhar, Chemical Abstracts 103:226308p (1980). *
Kihari, Chemical Abstracts 105:134160X. *
Maeda, et al., Japan Journal Cancer Research (Gaann, 77:523 525) (Jun., 1986). *
Maeda, et al., Japan Journal Cancer Research (Gaann, 77:523-525) (Jun., 1986).
Perez Soler et al., Cancer Research, 47:6462 6466 (Dec. 1987). *
Perez Soler, Cancer Research 46, 6269 6273 (1986). *
Perez-Soler et al., Cancer Research, 47:6462-6466 (Dec. 1987).
Perez-Soler, Cancer Research 46, 6269-6273 (1986).
Printout from Dialog Search. *
Ridgway, J. Clin. Hematol. Oncol. 7:220 229 (1977). *
Ridgway, J. Clin. Hematol. Oncol. 7:220-229 (1977).
Schwartz, Chemical Abstracts, 88:16014K (1978). *
Speer, Chemical Abstracts 84:54030n (1976). *
Sur, Oncology 40:372 376 (1983). *
Sur, Oncology 40:372-376 (1983).
Tzu, Chemical Abstracts 94:218774t (1981). *
Vollano, J. F., et al., Comparative Antitumor Studies on Platinum (II) and Platinum (IV) Complexes Containing 1,2 Diaminocyclohexane, J. Med. Chem. 1987, vol. 30, No. 4, p. 716 719. *
Vollano, J. F., et al., Comparative Antitumor Studies on Platinum (II) and Platinum (IV) Complexes Containing 1,2-Diaminocyclohexane, J. Med. Chem. 1987, vol. 30, No. 4, p. 716-719.
Yatvin, Proc. Am. Assoc. Cancer Res. 21:281 (1980). *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434256A (en) * 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5393909A (en) * 1988-11-22 1995-02-28 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5843475A (en) * 1996-12-06 1998-12-01 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes
US6696079B2 (en) 1996-12-06 2004-02-24 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes
US20040161456A1 (en) * 1996-12-06 2004-08-19 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes
US7029696B2 (en) 1996-12-06 2006-04-18 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes
EP2289549A2 (en) 1999-10-01 2011-03-02 Immunogen, Inc. Immunoconjugates for treating cancer
EP2266607A2 (en) 1999-10-01 2010-12-29 Immunogen, Inc. Immunoconjugates for treating cancer
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
CN107709286A (en) * 2015-06-24 2018-02-16 日本化药株式会社 New platinum (IV) complex compound
RU2695357C1 (en) * 2015-06-24 2019-07-23 Ниппон Каяку Кабусики Каися Novel platinum (iv) complex
US10988496B2 (en) 2015-06-24 2021-04-27 Nippon Kayaku Kabushiki Kaisha Platinum (IV) complex
US10596191B2 (en) 2015-09-14 2020-03-24 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of hexa-coordinated platinum complex
US11033577B2 (en) 2015-09-14 2021-06-15 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of hexa-coordinated platinum complex

Also Published As

Publication number Publication date
US5288887B1 (en) 1996-03-12
AU4484989A (en) 1990-06-12
US5288887A (en) 1994-02-22
WO1990005734A1 (en) 1990-05-31
US5318962A (en) 1994-06-07

Similar Documents

Publication Publication Date Title
US5041578A (en) Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
EP0155705B1 (en) Antitumor platinum complexes
US4115418A (en) 1,2-diaminocyclohexane platinum (ii) complexes having antineoplastic activity
US5194645A (en) Trans-pt (iv) compounds
EP0237450B1 (en) Platinum (iv) complexes
US5434256A (en) Diamine platinum complexes as antitumor agents
US4687780A (en) Anti-tumor compounds of platinum
US4739087A (en) Antineoplastic platinum complexes
US5028726A (en) Platinum amine sulfoxide complexes
US5008419A (en) Novel platinum complex
HU203246B (en) Process for producing antitumoural platinum(iv)-diamine complex and pharmaceutical compositions comprising such compound as active ingredient
US4175133A (en) 1,2-Diaminocyclohexane platinum (II) complexes having antineoplastic activity against L1210 leukemia
US4783482A (en) Bis(thiocyanato)palladium(II)complexes
KR20100107015A (en) Platinum complex compound and utilization of the same
US4578491A (en) Bis(thiocyanato)palladium(II) complexes
EP0214862B1 (en) Anti-tumour platinum complexes, their preparation and their use
US4831170A (en) Pharmaceutically active phospino-hydrocarbon-group VIII-metal complexes, antitumor compositions containing these complexes, and a process for preparing said compounds or antitumor compositions
EP0310260A2 (en) Platinum complexes and their use as anti-tumor agents
EP0261044B1 (en) Novel platinum-riboflavin-complexes
EP0098133B1 (en) Bis(thiocyanato)palladium(ii) complexes
JP2622852B2 (en) Platinum complexes and anti-neoplastic agents
JPH07101970A (en) Anti-tumor fat-soluble new platinum (iv) complex of cyclohexanediamine derivative
JPH04224596A (en) Platinum complex and antitumor agent
JPH02256690A (en) New platinum complex
JPS6230792A (en) Novel platinum complex

Legal Events

Date Code Title Description
AS Assignment

Owner name: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KHOKHAR, ABDUL R.;SIDDIK, ZAHID H.;NEWMAN, ROBERT A.;REEL/FRAME:005029/0283

Effective date: 19881118

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER;REEL/FRAME:021095/0128

Effective date: 19881122